The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether AstraZeneca is priced attractively today or already reflecting ...
AstraZeneca stock advanced in London trading on September 18, 2026 after CEO Pascal Soriot bought 60,000 shares at GBP 121.02 ...
An announcement from AstraZeneca ( ) is now available. AstraZeneca has disclosed a small share acquisition by its Chief Financial Officer, Dr Aradhana Sarin, under the company’s ...
AstraZeneca plc shares are trading slightly higher on the London Stock Exchange after a 3.1% gain in the US market on 06/04/2026, while investors reassess valuation metrics and growth prospects ...
Hosted on MSN
Below £151, here’s why AstraZeneca’s share price looks a steal to me under £228.62 after strong 2025 results
AstraZenecaâ s (LSE: AZN) share price looks to me to be anchored to an outdated view of its long-term earnings potential. This appears to reflect a mature, late-cycle pharmaceutical firm reliant on a ...
Mon, March 30, 2026 at 1:58 PM UTC AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date, the stock has gained 6.02%, though it ...
AstraZeneca remains a long-term buy, driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly stretched. AZN's 2025 results showed 8% revenue and 11% ...
LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above ...
AstraZeneca (AZN) stock gains 0.63% after CEO purchases £7.26M in shares and EU recommends Klygefa approval for rare ...
AstraZeneca share prices drop amid £300bn mega-merger talks with US rival - The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results